Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial

@article{Ray2017DevelopmentOT,
  title={Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial},
  author={L. Ray and S. Bujarski and S. Shoptaw and Daniel J O Roche and K. Heinzerling and K. Miotto},
  journal={Neuropsychopharmacology},
  year={2017},
  volume={42},
  pages={1776-1788}
}
  • L. Ray, S. Bujarski, +3 authors K. Miotto
  • Published 2017
  • Medicine
  • Neuropsychopharmacology
  • Current directions in medication development for alcohol use disorder (AUD) emphasize the need to identify novel molecular targets and efficiently screen new compounds aimed at those targets. Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor and was recently found to reduce alcohol intake in rats by ∼50%. To advance medication development for AUD, the present study consists of a randomized, crossover, double-blind… CONTINUE READING
    46 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Alcohol use disorder (AUD) is a prevalent and disabling psychiatric disorder with few, and only moderately efficacious, treatment options. Consequently, the identification of novel… Expand
    ConditionsAlcohol Use Disorder
    InterventionDrug, Other
    Does the Neuroimmune Modulator Ibudilast Alter Food Craving? Results in a Sample With Alcohol Use Disorder
    • 3
    • PDF
    Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial
    • 14
    • PDF
    Advances in Pharmacotherapy Development: Human Clinical Studies.
    • 12
    Apremilast Alters Behavioral Responses to Ethanol in Mice: I. Reduced Consumption and Preference
    • 8
    Transcriptomic analysis reveals moderate modulation of macrophage migration inhibitory factor superfamily genes in alcohol use disorders
    • 1
    • PDF

    References

    SHOWING 1-10 OF 84 REFERENCES
    Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study.
    • 30
    Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
    • B. Johnson
    • Medicine, Chemistry
    • Biochemical pharmacology
    • 2008
    • 246
    Ibudilast for the treatment of drug addiction and other neurological conditions
    • 17
    Translating the neuroscience of alcoholism into clinical treatments: From blocking the buzz to curing the blues
    • 103
    The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse.
    • 67
    A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.
    • L. Ray, K. Hutchison
    • Medicine, Psychology
    • Alcoholism, clinical and experimental research
    • 2004
    • 297
    • PDF
    The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid‐dependent volunteers
    • 38
    A Translational Approach to Novel Medication Development for Protracted Abstinence
    • 7
    Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models
    • 38
    • PDF
    Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers
    • 36
    • PDF